Aula sobre Trasplantes de Órganos Sólidos - Roche Trasplantes

Tratamiento y Prevención - PonenciasBIBLIOGRAFÍA1. Wight D. Liver transplantation. En: Thiru S, Waldmann H, eds.Pathology and immunology of transplantation and rejection.Oxford: Blackwell Science Ltd., 2001; 262-299.2. Wiesner RH, Batts KP, Krom RAF. Evolving concepts in thediagnosis, pathogenesis, and treatment of chronic hepatic allograftrejection. Liver Transplant Surg 1999; 5: 388-400.3. An International Panel. Update on the international Banff schemafor the liver allograft rejection: working recommendationsfor the histopathologic staging and reporting of chronic rejection.Hepatology 2000; 31: 792-799.4. Adams DH, Neuberger JM. Patterns of graft rejection followingliver transplantation. J Hepatol 1990; 10: 113-119.5. Prieto M, Argüello L, Berenguer J. Rechazo crónico. En: BerenguerJ, Parrilla P, eds. Trasplante hepático. Madrid: EL-BA, S.A., 1999; 348-356,6. Garcia RFL, Garcia CE, McMaster P. Chronic rejection of the liver.The role of immunosuppression. BioDrugs 2000; 14: 283-297.7. Van Hoek B, Wiesner RH, Krom RA, Ludwig J, Moore SB. Severeductopenic rejection following liver transplantation: incidence,time of onset, risk factors, treatment, and outcome. SeminLiver Dis 1992; 12 : 41-50.8. Hubscher SG, Buckels JA, Elias E, McMaster P, Neuberger J.Vanishing bile-duct syndrome following liver transplantation:is it reversible?. Transplantation 1991; 51: 1004-1010.9. Noack KB, Wiesner RH, Batts K, van Hiek B, Ludwig J. Severeductopenic rejection with features of vanishing bile ductsyndrome: clinical, biochemical, and histologic evidence forspontaneous resolution. Transplant Proc 1991; 23: 1448-1451.10. Sher LS, Howard TK, Podesta LG, Rosenthal P, Vierling JM,Villamil F, Tzakis A, Starzl TE, Makowka L. Liver transplantation.En: McIntyre N, Benhamou J-P, Bircher J, Rizzetto M,Rodes J, eds. Oxford tetxbook of clinical hepatology, 1ª Ed. Oxford:Oxford University Press, 1991; 1429-1449.11. Wiesner RH. Advances in diagnosis, prevention, and managementof hepatic allograft rejection. Clin Chem 1994; 40: 2174-2185.12. Jain A, Dmetris Aj, Kashyap R, Blakomer K, Ruppert K, KhanA, Rohal S, Starzl TE, Fung JJ. Does tacrolimus offer virtual freedomfrom chronic rejection after primary liver transplantation?Risk and prognostic factors in 1,048 liver transplantations witha mean follow up of 6 years. Liver Transpl 2001; 7: 623-630.13. Starzl TE, Todo S, Fung J, Demetris AJ, Venkataramman R,Jain A. FK 506 for liver, kidney, and pancreas transplantation.Lancet 1989; 2: 1000-1004.14. Sher LS, Cosenza CA, Michel J, Makowka L, Miller CM,Schwartz ME, Busuttil R, McDiarmid S et al. Efficacy of tacrolimusas rescue therapy for chronic rejection in orthotopicliver transplantation. Transplantation 1997; 64: 258-263.15. Klein A and the US Multicenter FK506 liver study group. Tacrolimusrescue in liver transplant patients with refractory rejectionor intolerance or malabsorption of cyclosporine. LiverTranspl Surg 1999; 5: 502-508.16. Blakolmer K, Jain A, Ruppert K, Gray E, Duquesnoy R, MuraseN, Starzl TE, Fung JJ, Demetris AJ. Chronic liver allograftrejection in a population treated primarily with tacrolimusas baseline immunosuppression. Transplantation 2000;69: 2330-2336.17. Platz KP, Tullius GS, Mueller AR, Schumacher G, Nüssler N,Neuhaus R, Bechstein WO, Lobeck H, Neuhaus P. Incidenceand outcome of chronic rejection in CyA- and FK 506-treatedpatients. Transplant Proc 1996; 28: 3183-3184.18. Platz KP, Muller AR, Zytowski M, Bechstein WO, Blumhardt G, LobeckH. OKT3 vs FK 506 rescue management of acute steroid-resistantand chronic rejection. Transplant Proc 1995; 27: 1111-1113.19. Gavlik A, Goldberg MG, Tsaroucha A, Webb MG, Khan RT,Weppler D, Nery JR, Khan MF, Zucker K et al. Mycophenolatemofetil rescue therapy in liver transplant recipients. TransplantProc 1997; 29: 549-552.20. Platz KP, Mueller AR, Neuhaus R, Keck HH, Lobeck H, NeuhausP. FK 506 and mycofenolate mofetil rescue for acute steroid-resistantand chronic rejection after liver transplantation.Transplant Proc 1997; 29: 2872-2874.21. Hebert MF, Ascher NL, Lake JR, Emond J, Nikolai B, Linna TJ, RobertsJP. Four-year follow-up of mycophenolate for graft rescue inliver allograft recipients. Transplantation 1999; 65: 707-712.22. Kato T, Ruiz p, DeFaria W, Weppler D, Khan F, Pina A, NeryJ, Tzakis A. Mycophenolate mofetil rescue therapy in patientswith chronic hepatic allograft rejection. Transplant Proc 1999;31: 396.23. Nishida S, Pinna A, Verzaro R, Levi D, Kato T, Khan F, NeryJ, Weppler D, Tzakis A. Sirolimus (rapamycin)-based recue treatmentfollowing chronic rejection after liver transplantation.Transplant Proc 2001; 33: 1495.24. Clemente G, Durán F, Loinaz C, Casanovas T, Rimola A, JaraP, Cuervas Mons V et al. Late orthotopic liver retransplant:indications and survival. Transplant Proc 1999; 31:511-514.25. Kashyap R, Jain A, Reyes J, Demetris AJ, Elmagd KA, DodsonSF, Marsh W, et al. Causes of retransplantation after primaryliver transplantation in 4000 consecutive patients: 2 to19 years follow-up. Transplant Proc 2001; 33: 1486-1487.171